Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enhancing chemotherapy's efficacy: new agent has synergistic effect with standard drugs

17.04.2007
The new protein-targeted drug inhibited growth of human lung and colon cancer cells

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center. Fox Chase research presented during the 97th Annual Meeting of the American Association for Cancer Research in Los Angeles has found that a new chemical agent, MCP110, has a synergistic effect both in vitro and in vivo when used with current chemotherapy drugs such as taxanes (Taxol and Taxotere) and vinca-alkaloid compounds such as vincristine.

This synergistic effect—in which the effect of two agents is greater than the sum of their individual effects—appeared when using the combination of MCP110 and Taxol on laboratory cell cultures of human Kaposi’s sarcoma and mouse models carrying human lung and colon cancer cells.

“Together, these findings indicate that MCP compounds have potential to be effective in combination with other anticancer agents,” the authors concluded.

Vladimir Khazak, Ph.D., now director of biology at NexusPharma, Inc., in Langhorne, Pa., and formerly a postdoctoral associate in the Fox Chase laboratory of molecular biologist Erica A. Golemis, Ph.D., presented the research in an AACR poster session. The work also appears in the March 1 issue of the AACR journal Molecular Cancer Therapeutics (“In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway—and microtubule-targeting inhibitors”).

The work builds on prior findings published by the team in the Proceedings of the National Academy of Sciences, which first identified MCP compounds, and demonstrated that MCP compounds have the ability to inhibit the growth of cultured cancer cells that depend on interactions of the Ras and Raf oncogenes—growth-promoting genes that can transform cells to cancerous ones if the oncogene is activated inappropriately.

The growth signals sent by these oncogenes use a well-traveled enzyme pathway called MAPK (mitogen-activated protein kinase). This pathway is responsible for cell response to various growth factors and is involved in the action of many cancer-causing genes.

A number of new cancer drugs in development such as MCP110 target this pathway to inhibit one or more steps in the growth signaling process. However, many established cancer chemotherapy drugs are cytotoxic—cell-killing—drugs that work in different ways, such as damaging their DNA or attacking the cells’ architecture. Several widely used drugs, including paclitaxel (Taxol), docetaxel (Taxotere) and long-time standby vincristine, take the latter approach, targeting important cell components called microtubules.

“Very few clinical agents are as successful by themselves as they are in combination,” Golemis pointed out. “Combination chemotherapies may use two drugs that either have the same target or two different targets. Another approach—the one we’ve taken here—is to combine a pathway-targeted drug with conventional chemotherapy.

“We’ve found that MCP110 synergizes both with other small molecules targeting the MAPK pathway and with multiple cytotoxic drugs. These studies predict that MCP110 is a potentially useful treatment agent for combination chemotherapy.” In addition to Khazak and Golemis, co-authors include Fox Chase visiting scientist Natalia Skobeleva, Ph.D., of St. Petersburg Polytechnical Institute in St. Petersburg, Russia, NexusPharma chemistry director Sanjay Menon, Ph.D.(formerly associated with NexusPharma and now at Boehringer Ingelheim Pharmaceuticals, Inc.,), and NexusPharma executive director Lutz Weber, Ph.D.

Karen Mallet | EurekAlert!
Further information:
http://www.fccc.edu

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>